Quantum-Si Q2 Earnings Call Highlights
Quantum-Si (NASDAQ:QSI) reported Q2 2026 revenue of $344,000, down from $591,000 a year earlier, and a Q2 net loss of $23.5 million. The company said Proteus launch timing is revised to early 2027, with initial detection of 19 or 20 amino acids. It expects about $12 million annual operating-expense savings and full-year 2026 revenue near $1 million.
How this was made
The 30-second read
Why it matters
Investors get a detailed update on Proteus instrument design cycle, expected launch capabilities (19 or 20 amino acids at launch, all 20 during 2026), a shift to application-oriented library-prep kits, and updated cost actions with expected operating-expense savings benefits starting in Q4.
Market read
The call provides actionable updates on Proteus execution timeline, launch detection scope, and financial runway, which can drive microcap sentiment and positioning ahead of future early-access and commercial milestones.
What to watch
The initial commercial kit amino-acid count (19 vs 20) is unresolved, and the article does not quantify how the application-specific kit suite affects near-term consumables revenue or customer conversion speed.
Background
Quantum-Si is developing Proteus, a next-generation single-molecule protein sequencing system, and uses its Platinum instrument via a placement program to generate customer insights.
Ticker impact
Quantum-Si reported Q2 revenue of $344,000 and reiterated 2026 guidance while shifting Proteus launch timing and instrument capabilities.
Near-term trading likely hinges on whether investors view the Proteus schedule slip and kit scope change as manageable versus a demand or execution risk.
The article contains concrete financials, cash runway through Q4 2028, and specific Proteus launch sequencing plus a revised detection target (19 or 20 amino acids at launch). However, it does not provide a new external catalyst like a contract, regulatory event, or updated consensus-beating guidance beyond reiterated revenue and expense targets.
Market effects
Signals ongoing commercialization friction in proteomics instrumentation, with emphasis on application-specific kits and sensitivity requirements for workflows.
No clear regional market catalyst beyond US-listed microcap sentiment.
Mentions European biopharma evaluation of AAV serotyping, suggesting international customer validation remains a key demand driver.
Counterpoint
The Proteus launch and early-access timing shift could be interpreted as de-risking instrument validation, improving odds of meeting sensitivity needs that Platinum could not deliver for routine workflows.
Key entities
- companyQuantum-Si Inc
Life sciences instrumentation company developing semiconductor-based proteomics sequencing platform Proteus and Platinum placement program.
- executiveJeff Keyes
CFO who reported Q2 financial results, cost actions, cash runway, and reiterated 2026 guidance.
- productProteus
Next-generation proteomics instrument whose launch schedule and detection capabilities were updated in the call.
